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Selective Reduction of Heart Rate with the Sinus
Node Inhibitor Zatebradine (ULFS 49) Does not Lead
to the Expected Improvements in Exercise Duration
in Patients with Angina Pectoris
Stephen P. Glasser, David Michie, Udho Thadani, Wolfgang M. Baiker, Zatebradine
Investigators I. University ofSouth Florida, Tampa, FL
Zatebradine is a novel compound blocking selectively the iF-channel in the
sinus node, which is believed to be the pacemaker current. Its effect on
heart rate is believed to be very selective, without any other effects on the
myocardium. Since it is widely believed that the beneficial effects of beta-
blockers are due to their heart rate reducing properties, selective reduction
of heart rate without negative inotropy should result in prolongation of exer-
cise duration and reduction in myocardial ischemia in patients with angina
pectoris. To investigate this hypothesis we performed a multicenter, random-
ized, double-blind, placebo-controlled, dose ranging study with zatebradine.
Patients (n-237) with reproducible exercise induced angina pectoris with evi-
dence of myocardial ischemia (?: 1 mm ST-segment depressionI received ei-
ther placebo, 2.5, 5.0 or 7.5 mg zatebradine for 4 weeks. Symptom limited
exercise tests were repeated at 3 and 12 hours post dose after 4 weeks of
treatment.
Change Placebo Zatebradine
from 3 h pa 12 h pa 2.5 mg 5.0 mg 7.5 mg
Baseline
12 h pa 3 h pa 12 h pa3h 12 h 3 h pa
Total ETD 30 30 33 25 42 28 50 38
(s)
Time 1 Min 24 34 27 33 57' 34 57 ' 48
(s)
HR Rest 1.8 0.5 -6.4*** -6.2**- ~12.1*** -8.0**· -20.5**· -13.7***
(bpm)
HR Ex 3.8 3.8 -5.9**· -5.5*** ~ 10.9*** -9.6*** -19.2**· -14.4***
(bpm)
EXSBP -2.3 -04 6.4*'" 3.2 5.4' 4.1 3.4 60
(mmHg)
h = hours, p.a. = post administration,s = seconds.•p< 0.05. **p< 0.01, ***p< 0.001,
ETD = exercise test duration, HR = heart rate. EX = Exercise, SSP = Systolic Blood
Pressure
Conclusion: Zatebradine is a powerful agent that reduces heart rate dose-
dependently over at least 12 hours. The observed heart rate reduction did not
translate into the expected improvements of exercise performance or reduc-
tion of myocardial ischemia suggesting that the anti-ischemic effect of heart
rate limitation should be reconsidered.
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1723-21 Selective Antagonism of Adenosine A1 Receptor
Mediated Effects in Humans with N-0861 ,
(N6-Endonorboran-2-yl-9-Methyladenine)
Barry D. Bertolet, Elizabeth A. Franco, Richard A. Kerensky, Wilmer W. NiChols,
Luiz Belardinelli, James A. Hill. University of Florida, Gainesvlile, FL
To determine the receptor subtype selectivity of the novel A1-adenosine
(ADO) receptor (R) antagonist, N-0861, the A1 and A2 R-mediated cardiac
effects were investigated in 13 patients during continuous Lv. infusion and
boluses of ADO before and after Lv. infusion of N-0861. Also, we sought to
determine the effects of N-0861 on ADO-induced chest pain.
Methods: Measurements of A-H interval (A1 effect), and coronary blood
flow velocity (CBFV) (A2 effect) were made before and after low dose (70
",g/kg) i.v. infusion and bolus (3 mg) ADO. N-0861 (0.25 mglkg) was infused
and the protocol repeated. At each stage, patients rated any chest discomfort
from 0 (no pain) to 10 (very severe pain) using a Borg Pain Scale.
Results: No adverse effects of N-0861 were noted. No evidence of myocar-
dial ischemia occurred during any part of the protocol. Chest discomfort oc-
curred in 11 patients and was transient, ending shortly after the ADO infusion
was terminated.
°expressed as percent increase over baseline;
*p < 0.05 compared to ADO alone
N-0861 abolishes the negative dromotropic effect and chest discomfort ex-
perienced during infusion of ADO, and attenuated discomfort observed dur-
ing the boluses of ADO.
Conclusions: 1) These actions of N-0861 support the conceptthat the neg-
ative dromotropic effect and angina-like pain caused by ADO are A1-ADO R
mediated; whereas, the increase in CBFV is due to activation of A2-ADO R's.
2) N-0861 appears to be an effective and selective A1-ADO R antagonist in
man. 3) In the presence of N-0861, ADO is a selective short-acting A2 sub-
type R agonist.
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1723-31 Endothelin in the Skin Microcirculation of Patients
with Coronary Heart Disease: Effect of Endothelin
Antagonist and Calcium Antagonist
Rene R. Wenzel, Georg Noll, Nadine Duthiers, Thomas F. Luscher. Cardiology,
University Hospital, Bern, Switzerland
Endothelin, a potent vasoconstrictor peptide released from endothelial cells,
is elevated in different cardiovascular diseases, I.e. atherosclerosis, acute
myocardial infarction, diabetes mellitus and pulmonary hypertension. The ef-
fects of the ETA-endothelin receptor antagonist PO 147953 (PD; 10-8 mol)
and the calcium-antagonist diltiazem (D; 10-7 mol) on endothelin-1 (ET;
10-12 mol) induced changes in blood flow of skin microcirculation were stud-
ied in 10 patients (7 male, 3 female) with angiographically documented coro-
nary heart disease (CHD) and in 10 healthy controls with a newly developed
double injection model. Changes in blood flow were assessed with laser-
Doppler-flowmetry. Data are shown as mean difference from saline ± SEM.
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Conclusions: In patients with CHD, the vasoconstriction to endothelin-1 is
reduced compared to healthy young controls.
The calcium-antagonist diltiazem inhibits endothelin induced vasocon-
striction in healthy volunteers and in patients with CHD. The endothelin-
antagonist PO 147953 fully prevents endothelin-induced vasoconstriction in
the skin microcirculation of patients with CH 0 in a 10 times lower concentra-
tion than the calcium antagonist.
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1723-4\ Cardiovascular and Neurohormonal Effects of SDZ
WAG 994, a Selective Adenosine A1 Receptor
Agonist, in Man
Inder Anand, Y. Chandrashekhar, Anne McCauley, Susan Ziesche, Michelle Berg,
Dianne Judd, Nardev Khurmi, Jay N. Cohn. VA Medical Center & University of
Minnesota, Minneapolis
Adenosine is the treatment choice for paroxysmal supraventricular tachycar-
dia (PSVT). However, short half life and lack of an oral preparation limits its
use. SDZ WAG 994 is a new orally active selective adenosine A1 receptor
agonist. Its rapid action and sustained effect (6 - 8 hr) might be advanta-
geous in the treatment of PSVT. It also produces presynaptic inhibition of
norepinephrine release but its effects in man have never been tested. We in-
vestigated the effects of oral administration of 2 & 5 mg SDZ WAG 994 on
exercise parameters -Iheart rate - HR, blood pressure, Anaerobic Thresh-
old, Peak V02 &Ventilatory indices) &Neurohormones in 12 normal subjects
in a single blind, placebo baseline-controlled, dose escalating design. SDZ
WAG 994 did not affect resting HR but the 2 mg dose caused a decrease
in peak exercise HR (by 11 beatslmin, p < 0.01). The 5 mg dose had no fur-
